Cleveland Clinic appoints cancer immunology expert as program director
Click Here to Manage Email Alerts
J. Joseph Melenhorst, PhD, has been appointed director of Cleveland Clinic’s new cell therapy and immuno-engineering program.
Melenhorst also will serve as vice chair of Center for Immunotherapy and Precision Immuno-Oncology.
He will lead the institution’s cell therapy developmental therapeutics program, with an emphasis on translating research into novel cellular therapies. He also will work with Cleveland Clinic experts to advance immuno-oncology research and treatment.
“Immunotherapy is the future of research in cancer and various other diseases, and Cleveland Clinic has made it a priority to establish a leading cell therapy program,” Timothy Chan, MD, PhD, chair of Cleveland Clinic’s Center for Immunotherapy and Precision Immuno-Oncology. “The program will empower clinicians and scientists to advance personalized cellular immunotherapy and further distinguish the Cleveland area as a top hub for cellular therapy development.”
Melenhorst, recognized for his expertise in cancer immunology, previously served as senior member of Center for Cellular Immunotherapies at University of Pennsylvania. While there, he helped implement chimeric antigen receptor T-cell therapy and other cell therapies into patient care.
He has conducted extensive research in translational and basic immunology. Some of his work has focused on the immunobiology of CAR T-cell therapies so they can be used to target cancers more effectively and safely.
Read more about
Click Here to Manage Email Alerts